Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC
Akari Therapeutics announced a strategic partnership with WuXi XDC to advance its novel antibody drug conjugate (ADC) platform, particularly accelerating the IND filing timeline of its lead candidate AKTX-101 to late 2026. The collaboration reinforces Akari's proprietary PH1 spliceosome-modulating payload technology and positions the company within…